Showing results 1 to 1 of 1
Issue Date | Title | Journal Title |
---|---|---|
2022 | ORCHARD platform study: Osimertinib plus datopotamab deruxtecan (Dato-DXd) cohort in patients (pts) with advanced NSCLC (aNSCLC) who have progressed on first-line (1L) osimertinib | ANNALS OF ONCOLOGY |